Page 1241 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1227

+
+
Multicompartment pharmacokinetics, skeletal, 474–491. See also specific types Na /K -ATPase, 229
45f, 46 neuromuscular blocking drugs, in cardiac contractility, 213, 215
Multidrug resistance-associated protein 474–475 digitalis on, 217
+
-
+
(MRP) transporters, 8, 8t preparations available, 490t Na /K /2Cl cotransporter (NKCC2 or
Multidrug resistance (MDR) genes, 38 spasmolytic drugs, 485–487, 488t–489t NK2CL), 257, 257f
Multidrug resistance type 1 (MDR1) Mushroom poisoning Nalbuphine, 555t, 556, 569, 572t
transporter, 8, 8t muscarinic receptor blockers for, 132 Nalmefene, 570, 572t
Multiple myeloma, 970–971 types of, 132–133 Naloxone, 570–571, 572t, 581, 588t, 659
Mu opioid receptors, 553, 554t Myasthenia gravis Naltrexone, 289b, 570–571, 572t, 588t
Mupirocin, 896, 1070 cholinesterase inhibitors for, 119 alcoholism treated with, 404, 406t, 407t
Muscarine, 109, 110f edrophonium for, 119 dependence and addiction, 588
Muscarinic alkaloids, direct-acting, 122t pathophysiology of, 119 Naltrexone/bupropion, 290t
Muscarinic (M3) acetylcholine receptors, Mycobacteria, 842 Nandrolone decanoate, 740–743, 741t.
parietal cell, 1087–1088, 1088f Mycobacterial drugs, 842–852, 851t. See also Androgens and anabolic
Muscarinic (M) receptors, 98, 99t See also Antimycobacterial drugs; steroids
M3 parietal cell, 1087–1088, 1088f specific agents Nanomaterials, toxic, 1017–1018
subtypes and characteristics of, 107–108, Mycobacterium avium, 850t Nanoparticles, as drug vehicles, 7
108f, 108t Mycobacterium avium complex (MAC), Naproxen, 645t, 648
subtypes of, 124 850, 850t Naratriptan, 291t, 296t
Muscarinic receptor blockers (antagonists), Mycobacterium intracellulare, 850, 850t Natalizumab, 995, 1112
124–129 Mycobacterium kansasii, 850, 850t Nateglinide, 759, 768t
adverse effects of, 133 Mycophenolate mofetil (MMF) National Health and Nutrition
anticholinergic, 135t, 136t immunosuppressive uses of, 987 Examination Survey (NHANES),
applications of, 130–133 rheumatoid arthritis treated with, 652 173
cardiovascular, 130–131 Mydriasis, 127, 128f National Research Council wound
cholinergic poisoning, 132–133 Myeloid growth factors (G-CSF, GM-CSF), classification criteria, 914b
CNS, 130 602t, 602–604, 603f, 606t Natpara, 775, 784
gastrointestinal, 131, 131t Myenteric plexus, 91f, 92 Natriuretic peptides, 308–309
ophthalmologic, 130, 130t Myocardial hypertrophy, 216 clinical role of, 310–311
respiratory, 126f, 130 Myocardial infarction, acute heart failure treated with, 225t
urinary, 131t, 131–132 female hormonal contraceptives as cause on kidney, 259
asthma treated with, 353–354, 354f. of, 735 pharmacodynamics and
See also specific drugs thrombolytics for, 618–619, 619b pharmacokinetics of, 309
chemistry and pharmacokinetics of, 125, Myocardial oxygen demand, 195, 195t preparations available, 318t
125f, 126f Myocardial oxygen supply, 195 synthesis and structure of, 308–309,
clinical pharmacology of, 130–133 Myoclonic seizures, 410, 430 309f
clinical uses of, 353–354, 359 Myrcludex B, 887 on vasoactive peptides, 317t
contraindications to, 133 Myxedema, 697 Natural killer (NK) cells, 977, 978
discovery of, 353 Natural killer-T (NKT) cells, 977, 978
mechanism of action, 125–127, 127t, N Nature of drugs, 3–5
353, 354f Nabilone, 582, 1106 physical nature in, 3
organ system effects in, 127–129 Nabiximols, 582 rational drug design in, 4
cardiovascular system, 94f, 111f, Nabumetone, 644f, 645t, 648. See also reactivity and drug–receptor bonds in,
127–129, 128f Nonsteroidal anti-inflammatory 3–4
CNS, 127 drugs (NSAIDs) receptor nomenclature in, 4–5
eye, 105f, 127, 128f N-acetylcysteine, 65, 73 shape in, 4
gastrointestinal tract, 127t, 129, N-acetyltransferases (NATs), 63, 64f, 67t size in, 3
129f Na channels, epithelial, 258, 258f Nausea and vomiting
+
-
genitourinary tract, 129, 129f Na /Cl cotransporter (NCC), 257, 257f pathophysiology of, 1103, 1104f
respiratory system, 129 Nadolol, 162, 164t, 166, 170t, 183. See of pregnancy, H 1 -receptor antagonists
sweat glands, 129 also b-receptor antagonist drugs for, 274
parkinsonism treated with, 501t, 508t NADPH-cytochrome P450 oxidoreductase NAV receptors, 560b
pharmacodynamics of, 125–129 (POR), 58, 60t–61t NDA, 15–17, 17
preparations available, 363t Nafarelin, 676, 739 Nebivolol, 164t, 166, 170t, 191t. See also
Muscarinic signaling, 110, 111f Nafcillin, 799 b-receptor antagonist drugs
Muscarinic stimulants, direct-acting, 120 Naftidrofuryl, 209 heart failure treated with, 221, 222, 225t
Muscle relaxants Naftifine, 861 hypertension treated with, 179t, 183
+
+
sedative-hypnotics, 389 Na /H exchanger (NHE3), 255, 256f structure of, 163f